Q4 2024 Evotec SE Earnings Call
Ladies and gentlemen, welcome to the Evotec SE full-year result 2024 analyst call. I am Yusef, the course call operator.
Speaker Change: I would like to remind you that all participants will be in this and only mode in that this conference is being recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star and one on your telephone. For operator assistance, please press star and zero. This conference must now be recorded for publication or broadcast. At this time, it's my pleasure to end over to Volker Brown. Please go ahead.
Volker Braun: Thank you Josef and the warm welcome to all of you following our webcast today. We will cover fiscal year 2024 results and will also share our 2025 guidance before we will be guiding you through the results of our strategic review process and share our midterm outlook with you.
Volker Braun: Before we do that it's my duty to point to the cautionary language which you find on page 2 and the second housekeeping item is to mention that this call is scheduled for up to two hours.
Volker Braun: It's no more pleasure trying the over-the-clock symbol Chesky, who will thank you for today's
Thank you.
Speaker Change: Good afternoon and thank you for taking the time to dial in. Before we go into content I would like to take the opportunity to welcome Paul Hitchin, our new CFO . Paul joined on March 1st and I'm excited to see such a great CFO complementing our management board.
Speaker Change: Paul and I will guide you through the presentation today. Let me first tell you how we will run this call.
You will obviously cover the 4 year 2024 results.
Speaker Change: And we will do this right at the beginning. We will then cover 2025. I will share our views on the current market environment. But I will also talk about the broader context in which we operate.
Speaker Change: This context will help you understand better why we are confident that it will take will enjoy accelerated growth in 2025 and beyond.
Speaker Change: This will then lead us to our strategy review.
Speaker Change: And our transformation program.
Speaker Change: We will approach this call in the same spirit I announced last time, providing clarity.
Speaker Change: A transparent approach.
Speaker Change: And reliability reliability also means.
Speaker Change: Living on what was <unk>.
Speaker Change: Promised.
Speaker Change: During our Q3 two.
Speaker Change: 2020 for itself.
Speaker Change: Oh, I announced that we will conduct a thorough evaluation of our strategy our operations.
Speaker Change: The organization is set up.
And all processes.
Speaker Change: With diligence and without bias.
Speaker Change: Half.
Speaker Change: Concluded this evaluation and I can reiterate what I said in November.
Speaker Change: Pairing it would take scientific excellence.
Speaker Change: With operational excellence is the way forward to deliver superior sustainable profitable growth.
Speaker Change: It will take today can rely on very strong fundamentals a world class scientific team.
Speaker Change: Cutting edge technology and outstanding customer relationships.
Speaker Change: Those fundamentals have carried remarkable revenue growth in the past.
Speaker Change: We will continue to build on it.
Speaker Change: On our journey to delivering profitable growth.
Speaker Change: You wouldn't know he is also talking about making the company.
Speaker Change: Strong, though not just bigger.
Speaker Change: We will address this later during the call let US now start first with full year 2024.
Speaker Change: They are encouraging developments to report on I'm quite pleased to say that after a number of rather rough previous quarters. It would take us come nicely around the corner with strong Q4 results.
Speaker Change: 2024 group revenues R&D expenditures and adjusted EBITDA are well within the guidance issued in summer last year, we've seen a strong year end finish.
Speaker Change: We've seen already in previous years. This Q4, however, sticks out as it has been the second best quarter ever in revenues with.
Speaker Change: Strong operational leverage.
Speaker Change: In 2024, we successfully strengthened many of our partnerships both in shared on D. N at just it will take biologics.
Speaker Change: Which are paving the way for long term growth and an overall, it's still a soft market environment.
Speaker Change: Like to single out a few highlights.
Speaker Change: Or just it will take biologics.
Speaker Change: The expansion of our partnership with Sandoz and expansion with other customers.
Speaker Change: Underpinning the strong growth dynamics.
Andi: It's shared Andi, our excellent collaboration with Bristol Myers Squibb.
Andi: It has been a true success story since many years.
Andi: Whilst we've seen recent decline in revenues, we just signed the extension of our multiyear collaborations in neuroscience and targeted protein degradation.
Andi: The new technology partnership with Novo Nordisk to support next generation cell therapies, and new multiyear Master research collaboration agreement with Pfizer initially focusing on early discovery research for metabolic and infectious diseases, and a new precision medicine partnership in cardio.
Andi: Allergy with buyer.
Andi: Those partnerships are a strong testament to our scientific excellence and are all based on it will take in house technology.
Andi: On the group level I would like to highlight that we have successfully implemented the party reset in Q1 this year.
Andi: I would like to now turn to Paul to guide us through our detailed Q4 and full year results hopefully.
Paul Hitchen: Christian and a warm welcome from my side.
Speaker Change: Let me guide you through our full year financial results in more detail.
Speaker Change: Full year 2024 group revenues reached 797 million euros, a 2% increase versus 2023.
Speaker Change: Our 2024 performance reflects two counterbalancing dynamics as we navigated a challenging year.
Speaker Change: Firstly, our shared R&D revenue declined from 673 million euros in 2023 to 611 billion euros and 24 in a persisting soft market.
Speaker Change: Approximately half of the reduction sanctioned BMS as we saw lower revenues in 2024, plus is a very strong 2023.
Speaker Change: This is only a temporary effect with a partner where we have seen very strong continued growth over recent years and which is expected to continue in the mid term.
Speaker Change: Looking forward, we have very strong BMS work packages and an excellent asset pipeline.
Speaker Change: In addition, we have seen a reduction in our discovery business, where we have seen a decline in the more fast turning transactional work.
Speaker Change: On the other hand, just EBIT like biologics continued to grow strongly.
Speaker Change: Reaching $185 6 million of revenue in 2024.
Speaker Change: Up from $108 4 million euros in 2023.
Speaker Change: This growth was 71% is driven by a strong order book of existing relationships and new deals.
Speaker Change: Our R&D spending is reduced by 26% versus prior year to 68, and a half million yours in 'twenty to 'twenty three to $50 9 million in 2024.
Speaker Change: As we direct our investments those most relevant for our partners.
Speaker Change: EBITDA reached $22 6 billion euros.
Speaker Change: Profit contribution from both shared R&D.
Speaker Change: And just you have a tech projects.
Speaker Change: Shed R&D contributed $12 7 million euros with full year adjusted EBITDA impacted by the softer revenues on the high fixed cost base with the full impact of the party reset program will only be effective in 2025.
Speaker Change: Adjusted <unk>, while the <unk> business reached a positive full year adjusted EBITDA of $9 9 million euros.
Speaker Change: Strong revenue growth compensated for a fourth quarter ramp up of costs for the Chile site.
Speaker Change: As a reminder.
Speaker Change: J Paul sight into lose was opened in September 2024.
Speaker Change: And is already generating revenue from P. M. P D activities in 2025.
Speaker Change: As we move to full operational readiness, we are triggering further ramp up costs in 2025 to support the committed business grows.
Speaker Change: To sum up we faced a challenging year driven by a high fixed cost base in combination with slow market demand for our R&D segments.
Speaker Change: The positive impacts of cost improvement initiatives together with a strong finishing the full quarter.
Speaker Change: I have driven an overall positive language landing within our guidance range.
Speaker Change: Let's now have a closer look at our quarterly performance.
Speaker Change: We achieved a strong fourth quarter with $221 2 million euros of revenues, a 20% revenue increase versus the third quarter.
Speaker Change: Overall for Q2 thousand 20 for revenue performance was the second strongest quarter ever.
Speaker Change: Benefiting from both the seasonality in fourth quarter and completion of key customer work packages.
Speaker Change: Our strong revenue performance in the fourth quarter, which translated into improved gross margin of 28% due to operational leverage and improved mix.
Speaker Change: When combined with the partial realization of priority reset cost saving initiatives. We overall delivered an adjusted EBITDA of $28 5 million euros.
Speaker Change: 33 million euro uplift versus the prior quarter.
Speaker Change: Cash flows have continued the positive trend in fourth quarter, reaching.
Speaker Change: Reaching a total operating and investing cash flow of $91 1 billion euros.
Speaker Change: The operating cash flow lenders $74 2 million euros in the fourth quarter.
Speaker Change: I wanted to highlight two axes measures that contributed to the increase.
Speaker Change: As part of our ongoing efforts to optimally leverage our balance sheet, we generated 50 million euros from R&D tax credit fracturing and 13 billion from income tax reimbursements.
Speaker Change: The positive investing cash flow in the fourth quarter of $16 9 million euros.
Speaker Change: <unk> benefited from the sale about minority recursion equity stake with proceeds of around 70 million euros.
Speaker Change: And lower Capex spending of 15 million euros, reflecting the planned slowdown of the capex investment rate relating to adjust EBIT expansion.
Speaker Change: Going forward, all Capex spend will move towards a new base level.
Speaker Change: Which however is expected to be above a whole quarter spending rates, but also well below the average for 2020 for spending.
Speaker Change: Our total liquidity, which includes cash and investments increased by 94 million euros versus third quarter <unk>.
Speaker Change: Leading to a year end balance of 397 million euros.
Speaker Change: Our net debt consequently improved to 43 million euros.
Speaker Change: And together with the improved last 12 months of adjusted EBITDA.
Speaker Change: We achieved a net debt leverage of one nine times and.
Speaker Change: In all financial covenants in the loan agreements with therefore complied with.
Speaker Change: Moving over to our balance sheet.
Speaker Change: <unk> currently has financial liabilities and lease obligations totaling 449 million euros split across research financing, a promissory notes and lease obligations.
Speaker Change: 95% of our financial liabilities carry a fixed interest rates with a well balanced maturity profile.
Speaker Change: Due to the fixed interest rates, we're offering also benefiting from low financing costs secured during the low interest environment.
Speaker Change: I want to mention that currently there is no active financial covenants.
Speaker Change: We agreed existing covenant waivers the drawn lines for the period of third quarter of 2014 fourth quarter of 'twenty five in.
Speaker Change: In addition, the covenant of our Undrawn, Austria was also waived until the end of the second quarter of 2025.
Speaker Change: We are in the process of renegotiating the terms with the Austrian banks based on our latest financial profile.
Speaker Change: Also last topic for 2024 I'll share details of the progress made on party resets.
Speaker Change: We are pleased with the progress that we're making in reengineering our cost structure.
Speaker Change: We have successfully completed the implementation of measures totaling 40 million euros of run rate savings that will be fully P&L visible in 2025 with about 10 million euros impact already included within our 2020 full financials.
Speaker Change: These savings are driven by successful divestment of our API business and Hello.
Speaker Change: The footprint reductions with site exits as well as building closures in Hamburg, Addington and getting it all completed in 2024.
Speaker Change: In addition, we completed the closure of our Columbus site and the end of February 2025.
Speaker Change: Our head Count result review resulted in approximately 280 completed role reductions by the end of 2024.
Speaker Change: And the remaining role reductions were completed in the first quarter of 2025.
Speaker Change: During the implementation phase we were able to further reduce the expected one off expenses to 55 million euros, representing a 13 million euro improvement versus our first estimation at the end of <unk>.
Speaker Change: First half 'twenty 'twenty four.
Speaker Change: To conclude.
Speaker Change: Alrighty reset has been successfully implemented and we will deliver 40 million euros of run rate savings.
Speaker Change: We will not stop there.
Speaker Change: What other cost saving measures identified during partially reset program together with additional cost efficiency measures will be actively pursued in 'twenty to 'twenty five.
Speaker Change: And more on this during our strategy in 2025 outlook.
Speaker Change: With that I hand back to Christian to share our thoughts on the developments in our markets and the underlying assumptions of our guidance for 2025.
Christian Wojcicki: Thank you Paul we see it will tick well positioned in the highly attractive resilient and growing markets with some temporary softness. So please allow me.
Christian Wojcicki: You allude to some fundamental features of our market before going into short term trends just it will take biologics is serving.
Christian Wojcicki: <unk> 15 billion pop growing biologics manufacturing market.
Christian Wojcicki: Within this space continuous manufacturing, it's the emerging trend.
Christian Wojcicki: If it comes with several strong technical operational and financial benefits over existing processes.
Christian Wojcicki: <unk> manufacturing therefore is expected to take share in a market that is already growing 10% per year.
Christian Wojcicki: At AMETEK.
Christian Wojcicki: The leader in continuous manufacturing we are shaping this new segment.
Christian Wojcicki: Shared R&D, we enable the biopharmaceutical industry to discover and develop drugs.
Christian Wojcicki: Trends in global R&D spending are therefore primary influencing factor for our business.
Christian Wojcicki: The total spend in global R&D is about 260 billion historically they have grown on average at mid single digit rates.
Christian Wojcicki: Biotech typically a bit faster big pharma, but slower.
Christian Wojcicki: After having witnessed very dynamic phase of above average funding.
Christian Wojcicki: And double digit growth of R&D budgets triggered by Covid fueled by zero interest rates. The market has now seen corrections in the recent years.
Christian Wojcicki: However, the fundamental drivers remain attractive.
Christian Wojcicki: And build the basis for resilient future growth I'd.
Speaker Change: I'd like to highlight three drive us firstly, the need for new drugs.
Speaker Change: The pharmaceutical industry is navigating towards a patent cliff with accumulated revenues of $200 billion of trucks, losing exclusivity by 2030.
Speaker Change: The need to refill pipelines is evident.
Speaker Change: The issue has become even more pressing F biomarker.
Speaker Change: Pharma companies have undergone pipeline revenues and cost saving programs.
Speaker Change: Simply to adjust internal cost structures.
Speaker Change: The industry collectively what have to refill the pipeline be it biotech or pharma to generate future growth.
Speaker Change: We expect global R&D budget to grow 3% to 4% per year over the coming period.
Speaker Change: With regaining focus on early drug discovery.
Speaker Change: Secondly, the trend towards outsourcing.
Speaker Change: Research services speed and breadth discovery and clinical stage provide flexibility for the industry by turning fixed costs into variable costs. We see this trend continuing with more and more activities moving from in house to external.
Speaker Change: Biotech companies are already making extensive use of it.
Speaker Change: While outsourcing and latest stage services have already grown to 40% in the last couple of years.
Speaker Change: The share for early drug discovery has potential to catch up.
Speaker Change: And see our own position in the fields like era attack will benefit over proportionally.
Speaker Change: Okay.
Speaker Change: We therefore expect growth for the drug discovery market to outpace R&D spending.
Speaker Change: We anticipate our underlying addressable market to grow 5% to 7% during the period 2024 to 2028.
Speaker Change: Finally.
Speaker Change: The trend towards next generation technology.
Speaker Change: Return on R&D money throughout the pharma industry has stagnated over.
Speaker Change: Or even declined over the last year's structural changes are required.
Speaker Change: The top 20 pharma companies collectively have terminated clinical trials, whereas seven $7 billion in 2024.
Speaker Change: At this stage many years of research have passed already.
Enabled tech we are committed to contribute.
Speaker Change: Step change improvements in probability of success.
Speaker Change: Graphically shortening the timeline.
Speaker Change: And decreasing the cost of drug discovery and development.
Speaker Change: The path forward is through.
Speaker Change: Through technology. This is our sweet spot.
Speaker Change: <unk> Tec has a unique set of capabilities.
Speaker Change: World class expertise in automation and industrialization as our heritage. We complement this with deep understanding of disease patents on Monica level.
Speaker Change: We apply AI to improve discovery and talks prediction.
Speaker Change: This allows <unk> to tap into a larger addressable market beyond the classical fee for service CLO space.
Speaker Change: While our base offering as research services, our proprietary technology allows us to create strategic partnerships.
Speaker Change: And gifts leeway for additional growth and value pools.
The recent announcement of the FDA to pivot away from animal testing towards AI supported prediction of toxicity.
Speaker Change: It's a clear signal of the direction of travel.
Speaker Change: Let us now turn to a more near term drive us quite a few of them of geopolitical and regulatory nature.
Speaker Change: To be clear right away, we anticipate the direct effect on Paris and budget cuts in the U S to be limited.
Speaker Change: As a service business our exposure to a traveling groups.
Hence the Paris is limited our direct exposure to NIH funding and related governmental budget cuts in the U S. It's small.
Speaker Change: On the flip side, we are ready and prepared to support our customers on potential implications of the bio secure act.
Speaker Change: And as mentioned before the recent announcement of the FDA on ml testing opens new opportunities for AMETEK.
Speaker Change: The macroeconomic situation, however is creating uncertainty for our customers and is still impacting the R&D spending in biotech.
Speaker Change: While funding seems to be improving money, if preferentially routed to late stage projects.
Speaker Change: As a result, we expect the demand from Biopharma.
Speaker Change: To remain soft throughout 2025.
Speaker Change: At 2024 levels.
Speaker Change: The tipping point toward growth is not yet reached.
Speaker Change: At the top end of our expectations. We expect this in the second half 2025.
Speaker Change: In sharp contrast.
Speaker Change: The biologics market for just <unk> biologics is very robust.
Speaker Change: And we remain highly confident about the short and long term future of this business.
Paul Hitchen: Paul will now speak about our guidance for this year.
Speaker Change: Okay.
Speaker Change: As we navigate an uncertain environment, we do see growth potential.
Speaker Change: And it's worth spending some time have the ability on the building blocks of our 2025 outlook.
Speaker Change: Yeah.
Speaker Change: We expected chipping.
Speaker Change: Earliest at the end of this year.
Speaker Change: Meaning our shared R&D business will continue to experience a softer market in 2025.
Speaker Change: However.
Speaker Change: Approximately one quarter of our business is exposed to the higher grades biologics markets well.
Speaker Change: We also benefit from existing strong strategic partnerships and new growth potential.
Speaker Change: Whilst we will provide some more updates our first quarter in 2025 on the May six updates we can say that we have seen a weak to start the year and shared R&D. However.
Speaker Change: However, we've also seen our strongest starts the year from adjusted EBIT <unk> business.
Speaker Change: As mentioned earlier.
Speaker Change: Our priority reset will lead to an additional 30 million gross savings in 2025.
Speaker Change: Our ongoing focus on tight cost control and cost initiatives. In addition to project resets.
Speaker Change: To compensate for onetime nonrecurring benefit seen in 2024.
Speaker Change: This continued focus on tight cost control remains a priority in 2025.
Speaker Change: And a new set of initiatives will launch in 2025 as part of our strategic plan, which will be outline shortly.
Speaker Change: Whilst our focus is on the lower cost curves. We also continue to invest in growth.
Speaker Change: The opening of J pop in France in September last year.
Speaker Change: And an acceleration of manufacturing readiness for our partners requires pre investments into opex as serving committed business beyond 2025.
Speaker Change: With this said.
Speaker Change: We would like to share our 2025 guidance with you.
Speaker Change: Group revenue is expected to grow 5% to 10% with 840 to 880 million euros drill.
Speaker Change: Driven by just <unk> biologics, we shed our R&D revenues at broadly similar levels to 2024, given the soft market environment.
Speaker Change: With upside potential if market tipping point is reached in the second half.
Speaker Change: We see strong progress with strategic partnerships, suggesting meaningful contributions from milestone payments over the next 24 months, yet more likely in 2026.
Speaker Change: Just if you could take politics revenue growing beyond the market growth rate is just livers on its strong order book and strong underlying new customer demands for the just EBIT Tech technology.
Speaker Change: We will continue to prioritize our R&D expenditure towards differentiated scalable platforms and technologies.
Speaker Change: Our group adjusted EBITDA is expected to be between 30 and 50 million euros.
Speaker Change: Sure and R&D will be the main contributor to group EBITDA in 2025.
Speaker Change: Project reset is delivering in full.
Speaker Change: We will see higher productivity in our operations as we drive further cost optimization and improve our existing equipment and infrastructure utilization.
Speaker Change: Adjusted <unk> business will see a higher ramp up costs for the to lose sight versus 2020 full as we pre interest to serve future customer committed business and continued high growth beyond 2025.
Speaker Change: Our overall adjusted EBITDA guidance reflects a balance of cost discipline and investments to support the growth of our just EBIT Tech business.
Speaker Change: I want to just spend a moment explaining the drivers of the 2024 to 2025 guidance.
Speaker Change: From a starting point for 2000 $23 million I'm, sorry from a starting point of $23 million.
Speaker Change: Guidance may appear a little light at first glance.
Speaker Change: So 30 million euros of incremental savings from party research, we've already bring us above $50 million your EBITDA level in 2025.
Speaker Change: However.
Speaker Change: The underlying improvement reflects consideration that full year 2020 for not only benefited from approximately $10 million of recurring savings related to priority resets. It also benefited from one time savings that will not recur in 2025.
Speaker Change: An example would be a reduction in our variable compensation.
Speaker Change: It was appropriate in a year, where we also saw an 8% reduction in our workforce.
Speaker Change: The negative impact of the nonrecurring 2020 for one off savings will be more than compensated by two liters.
Speaker Change: Firstly, we have launched further cost measures beyond priority research contributing approximately two thirds of the remaining updates.
Speaker Change: And secondly, the moderate shared R&D volume growth will be absorbed by our remaining workforce and thus largely dropped through to earnings.
Speaker Change: But just even take project segments.
Speaker Change: While anticipated you outpaced the market is not expected to contribute materially to the group's adjusted EBITDA in 2025 due to the continuation of the fourth quarter of 2020 full cost ramp up as we prepare for future committed demand.
Speaker Change: In short the business will drive improved operational discipline, while continuing to invest in our higher growth segments.
With that back to Christian.
Speaker Change: To sum this up after a challenging couple of quarters in 2023 and 2024, we landed the business along our guidance from summer.
Speaker Change: Well last quarter was strong and revenues and profit.
Speaker Change: Both for sure Andi and just it will take biologics.
Speaker Change: While we substantially improved our net debt ratio our turnaround continues in 2025.
Speaker Change: With revenue and profit going up in a still challenging market environment.
Speaker Change: More importantly, we are strengthening our backbone and stabilizing the business to allow us to drive operational leverage once growth in shirt on EBIT trends.
Speaker Change: And just we are committed to driving continued growth at a very high rate supported by sizable investments in our workforce in 2025.
Speaker Change: We're now opening a new chapter of our story towards profitable growth. So.
Speaker Change: Let us continue with a look into our strategy and the key elements of our transformation going forward.
Speaker Change: A quick reminder of our journey.
Speaker Change: The first quarter last year, we communicated at prior T resets.
Speaker Change: For the whole company towards profitable growth.
Speaker Change: As a consequence, we've made immediate adjustments to our business right.
Speaker Change: Rightsize capacity and deliver $40 million of savings.
Speaker Change: The reset has been successfully concluded.
Speaker Change: In November I, then announced the strategy revenue.
Speaker Change: As promised we've conducted this thoroughly with an unbiased view.
Speaker Change: It's gone very deep unfolded, our business assessed each component of it.
Speaker Change: Explored what customers really want from us is still the essence of our strength.
Speaker Change: Come up with a very clear compelling strategy for the company and the revised financial plan.
Speaker Change: So what is it about.
Speaker Change: And it will check.
Speaker Change: We strive for technology and science leadership in everything we do we are pioneers in drug discovery.
Speaker Change: With our partners, we accelerate that journey from concept to cure.
Speaker Change: We achieved this by leveraging our cutting edge technology.
Speaker Change: Disruptive signs.
Speaker Change: And AI driven innovation.
Speaker Change: We are focusing on two business pillars.
Speaker Change: Drug discovery and preclinical development.
Speaker Change: As well as just it would take biologics.
Speaker Change: This means adjustments to our business model, simplifying and focusing shared on D and.
Speaker Change: Enhancing just AMETEK biologics.
Speaker Change: We will adapt our way of working will generate growth momentum with a new targeted commercial model.
Speaker Change: Our commitment to operational excellence will lead to a transformative step change in our performance.
Speaker Change: We will prioritize and focus on developing our talent.
Speaker Change: Recognizing that our people.
Speaker Change: Are the driving force behind our success.
Speaker Change: Alongside our transformation, we're establishing a clear structure dedicated responsibilities transparent decision, making accountability and.
Speaker Change: And avoiding.
Speaker Change: Any kind of cetus.
Speaker Change: Sustainability for us as a business case, reducing lepton.
Speaker Change: And thus energy minimizing waste optimizing natural resources. These are all essential factors for us in running our business.
Speaker Change: As responsibly as possible and supporting our partners and ambition.
Speaker Change: As Seth the umbrella of our strategy is differentiation through technology and science leadership.
Speaker Change: This 10 years, our view for the future business portfolio.
Speaker Change: We will preferentially invest in opportunities.
Speaker Change: That further strengthen our leadership profile opportunities that make the company stronger not just bigger.
Speaker Change: We are simplifying the shift on the business model.
Speaker Change: Our intent is to enable our partners to accelerate drug discovery drill.
Speaker Change: Driven by technology.
Speaker Change: Not to build our own biotech pipeline.
Speaker Change: Our scope is sharply defined from target I'd to R&D.
Speaker Change: Decision is based on our strength.
Speaker Change: And our customer decision points, we will not be in clinical development.
Speaker Change: We recognize the different dynamics and characteristics of individual services within this scope.
Speaker Change: Some of them Commoditizing, while others are true high tech and yet others with.
Speaker Change: Well massively benefit from next generation technology.
Speaker Change: Unfolded all of this.
Speaker Change: And we will preferentially invest into high growth high value tech driven segments, where automation.
Speaker Change: An industry utilization of our key.
Speaker Change: Or just it will take biologics, we will operate our model.
Speaker Change: This business is a world leader in developing enabling technologies for.
Speaker Change: Our end to end continuous manufacturing.
Speaker Change: We are excited about the value proposition of just our near term focus is on even better monetizing.
Speaker Change: Our leading technology and existing assets.
Speaker Change: We're spending significant time exploring options here, we're not contemplating investing into a J P. Three.
Speaker Change: During the current planning horizon.
Speaker Change: And.
Speaker Change: Allow me to say it will be very capital efficient going forwards.
Speaker Change: Yeah.
Speaker Change: With our new strategy, where I'll be focusing it would take.
Speaker Change: On its core strengths to deliver maximum impact for our customers and patients worldwide.
Speaker Change: Rest assured this strategy is already in execution.
Speaker Change: We've streamlined our asset pipeline by 30%.
Speaker Change: Focusing on high quality high potential assets.
Speaker Change: As part of our cleaning up we've divested EBIT to Iran and stopped activities in other projects.
Speaker Change: Which is not anymore meet our high quality high potential criteria.
Speaker Change: Going forward, we are focusing our R&D spend on further developing our proprietary platform technology investments into one on partnered assets.
Speaker Change: A limited to scientific proof points.
Speaker Change: This is reflected in a reduction.
Speaker Change: After flight level of R&D spending in 2025.
Speaker Change: Instead R&D the concept of risk sharing.
Speaker Change: And.
Speaker Change: Opportunity sharing will be limited to high value strategic partnerships.
Speaker Change: This is also a sneak privy or we might want to reflect the adjusted strategy.
Speaker Change: And adjusting the name of this reporting segment in future.
Speaker Change: Our strategy is not to act as a V. C player we have therefore already reduced our equity participation exposure.
Speaker Change: With intent to exit over time.
Speaker Change: As you heard earlier, we sold our shares with the Caribbean in a very favorable time window, leading to an overall strong IR office investments finally.
Speaker Change: As mentioned before we are actively exploring opportunities to upgrade our model. It just it will take biologics.
Speaker Change: Contemplating ways to better leverage existing technologies and resources in a more capital efficient way.
Speaker Change: Technology insight leadership is our heritage and our sweet spots the company originated and making high throughput screening accessible for industrial purposes.
Technology and Science leadership is also what our customers expect from us.
Speaker Change: And we have been told over and over again that this is where it will take really excels.
Speaker Change: But it also provides us with access to growth beyond the classical CLO services as we spoke about before.
Speaker Change: Traditional ways of running R&D projects are coming to its limits.
Speaker Change: Well standardized services are increasingly outsourced additional growth will be fueled by next generation technology platforms and able tech.
Speaker Change: He is leading this waste.
Speaker Change: For example, we have pioneered the field of Omics.
Speaker Change: We're currently running one of the largest research initiatives in this field.
Speaker Change: If deeply.
Speaker Change: Embedded stem cell technologies and molecule patient databases, and our scientific expertise.
Speaker Change: In our toolbox, we're using AI and AI for coda platform to accelerate that journey for drug discovery.
Speaker Change: And to improve prediction.
Speaker Change: We lead in cell therapy technologies.
Speaker Change: And we are reinventing biologics manufacturing with just it will take biologics all of which are playing in market growing at healthy double digit rates.
Speaker Change: All of this goes well beyond classical Thea all services E C O essentials.
Speaker Change: Our technology allows us to strike strategic deals it puts us at.
Speaker Change: At the higher range.
Speaker Change: Well, if a market growth perspective.
Speaker Change: And it generates additional value pool upsides.
Speaker Change: In conclusion, we are convinced that it will take will be trending to above market growth rates and industry industry leading margins.
Speaker Change: You will see sizable contribution already within the next two to three years reflected in our mid range plane plan and.
Speaker Change: And further accelerating thereafter.
Speaker Change: As we speak.
Speaker Change: We are adjusting our commercial model.
Speaker Change: Fresh approach, that's AR balances our established strength in.
Speaker Change: In long term high value strategic collaborations.
Speaker Change: While leveraging our platform to its full extent for Standalone projects.
Speaker Change: In the center of all considerations is the question of how we create best possible value for our clients.
Speaker Change: And how we can create a more scalable model.
Speaker Change: Industrialization and automation of the basis to deliver excellent results no matter. If we talk about a single experiment in the lap for them.
Speaker Change: Multiyear strategic collaboration.
Speaker Change: The more standardized offering as.
Speaker Change: That's the focus on speed.
Speaker Change: And ease of doing business.
Speaker Change: With us.
Speaker Change: At industry, leading quality standards.
Speaker Change: Additional services are provided in our integrated projects here, our customer benefit customers benefit.
Speaker Change: From a one stop shop approach integration.
Speaker Change: And parallel work allow for faster generation of results.
Speaker Change: An important element is also getting access to expertise of our people and the benefit from consulting services.
Speaker Change: The gold standards of our offering becomes part of our strategic partnerships.
Speaker Change: Where we create long term calibration.
Speaker Change: And these collaborations our customers get exclusive access.
Speaker Change: Our proprietary technology to predict.
Speaker Change: Critic area of expertise and IP.
Speaker Change: In exchange of value add on revenue components.
Speaker Change: Such as milestones licenses and royalties.
Speaker Change: Our revised strategy is centered around technology and science leadership in support of this our internal R&D will focus on developing our technology platforms for drug discovery.
Speaker Change: We will continue to do very selective investments in early stage higher.
Speaker Change: Highly differentiated assets on our own behalf.
Speaker Change: Those serve as valuable proof points of the effectiveness of our technology and they open the door for strategic collaborations.
Speaker Change: We've only advanced those assets beyond early stage as part of the strategic partnership.
Speaker Change: This collaborative approach ensures limited financial risk exposure.
Speaker Change: While offering attractive financial upsides.
Speaker Change: It will take today co owns an impressive pipeline of assets.
Speaker Change: Uprising over 100 individual assets.
Speaker Change: Around 70% of those are partnered with top pharma companies.
Speaker Change: They target nature here predict areas.
Speaker Change: Those partnerships provide research payments those partnerships provide research payments.
Speaker Change: To further develop the assets plus significant financial upside in terms of success based milestone payments and royalties.
Speaker Change: By collaborating with multiple partners across diverse therapeutic.
Speaker Change: Can you predict areas.
Speaker Change: We are mitigating the risk profile, but also significantly enhancing the likelihood of bringing drugs to market.
Speaker Change: In line with our strategic revenue.
Speaker Change: We streamlined our asset pipeline and we will focus on high quality high potential assets.
Speaker Change: Today these are around 100 efforts.
Speaker Change: With six in clinical and 16 preclinical stage.
Speaker Change: Over the next 24 to 36 months, we aim to further elevate the quality of the pipeline.
Speaker Change: Progressing and increasing the number of clinical and preclinical assets.
Speaker Change: The revenue potential for AMETEK until 2045 is around 16 billion euro based on milestone payments and royalties. This obviously non risk adjusted.
Speaker Change: Our partnerships with BMS are particularly promising with it would take eligible to receive over 7 billion Europe and milestones for its work on more than 30 assets.
Speaker Change: In the three years to come.
Speaker Change: The potential is more than $500 million increasing to over $1 2 billion in the next five years.
Speaker Change: Allow me to say, we've taken a conservative approach and risk weighting the potential for our mid range plan.
Speaker Change: A few more words about just it will take biologics we are excited about the business.
Speaker Change: Our revenues have grown from about $40 million in 2021 to over $180 million in 2024.
Speaker Change: As we build and diversify our customer portfolio you will see just it will take biologics continuing to enjoy very healthy growth. This.
Speaker Change: 50 and beyond.
Speaker Change: We think that the potential of this asset is not yet fully exploited.
Speaker Change: And we're spending a lot of time.
Speaker Change: Thinking about better monetizing our technology and assets.
Speaker Change: Along our group strategy remember technology and science leadership.
Speaker Change: We are exploring options to further expand our leadership position in the process technology in cell lines and others.
Speaker Change: This will come with expanding our commercial model with.
Speaker Change: With confidence that we can enlarge our addressable market beyond the classical CD more space.
Speaker Change: We're pivoting.
Speaker Change: Towards our Capex lighter model.
Speaker Change: Well the current planning period, we're not contemplating to invest into a network of J Potts.
Speaker Change: We expect to share an update on the just <unk> biologics strategy and those details for the Q3 call.
Paul Hitchen: Now, let us move on to look at some financial implications Paul Please.
Paul Hitchen: Thank you Christian.
Paul Hitchen: Our improvements in governance and performance transparency are already well underway.
Paul Hitchen: From the formation of active transformation and commercial committees to the institution of structured capex approval processes.
Paul Hitchen: As you have seen we have a commitment to operational excellence will.
Paul Hitchen: We will be committing to your gross.
Cost efficiency program of a further 50 million euros between 25, and 2000 and for G. H.
Paul Hitchen: In the immediate future.
Paul Hitchen: Optimizing our operating model and organizational structure.
Paul Hitchen: I'll provide the necessary conditions to drive our transformation and pivot to operational excellence.
Paul Hitchen: Okay.
Paul Hitchen: We have identified tangible leavers to address all footprint overcapacity.
Paul Hitchen: Our inefficient processes, whilst reducing complexity within our SG&A.
Paul Hitchen: Over the mid term.
Paul Hitchen: We will drive further operational leverage.
Paul Hitchen: Automation and industrialization of our operations.
Paul Hitchen: Our strategy will realize sizable progress in the next two to three years with a refined footprint improving gross margins smartly to SG&A and careful R&D investments, all improving profitability, while sharpening our competitive edge and driving long term.
Paul Hitchen: <unk> growth.
Paul Hitchen: We firmly believe that our scientific excellence, coupled with operational excellence will translate into material value creation.
Paul Hitchen: The depth of our innovation and differentiated technology combined with improved focus on operational efficiency.
Paul Hitchen: Set us on course to grow faster than the market.
Paul Hitchen: High single digit or low double digit percentage rates and to generate EBITDA margins over 2000.
Paul Hitchen: 20%.
Christian Wojcicki: And with that Christian to wrap up.
Christian Wojcicki: So to conclude the introduction of our new strategy, we have a clear value creation plan centered around four core pillars, firstly above market growth rates are better quality earnings drill.
Christian Wojcicki: Driven by our technology.
Christian Wojcicki: Leadership and innovation.
Christian Wojcicki: This will be supported by our focus on higher value generating market segments with above average growth rates.
Christian Wojcicki: And strong margins that require a differentiated offerings.
Christian Wojcicki: Secondly, we're committed to driving operational excellence as part of this.
Christian Wojcicki: <unk> launched additional optimization measures.
Christian Wojcicki: But I expect it to drive more than 50 million cost out by 2028 on top of existing commitments.
Christian Wojcicki: We are furthermore, expecting additional productivity gains to continued operational leverage.
Christian Wojcicki: Through to 2028 as the market recovers.
Just it would take biologics as a core pillar of our profitable growth, we will realize the growth commitments.
Christian Wojcicki: Existing and new partnerships.
Christian Wojcicki: While focusing on further improving the monetization of our existing technology and assets.
Christian Wojcicki: In addition.
We have a strong pipeline of assets with credible partners and significant associate milestones and royalties.
Christian Wojcicki: Thank you and now the management board and I.
Christian Wojcicki: Looking very much for watts to taking your questions.
Speaker Change: Back to the operator, please start the Q&A.
Speaker Change: Ladies and gentlemen, we will now begin the question and answer session anyone who wishes to ask a question with Westar and one under telephone you will hear a tone that come from the just entered the queue. If you wish to remove yourself from the question you May Press Star and two participants are requested to only use handsets will asking a question anyone to ask a question May press.
Star and one at this time. The first question comes from Christian Ehmann Warburg Research. Please go ahead.
Christian Ehmann: Hello, everyone and thanks for taking my question.
Christian Ehmann: I have a couple of if you indulge me so I'm I would like to start off although I appreciate the global overview and then a strategic update I would like to start with a more local question.
Christian Ehmann: So first of all for the.
Christian Ehmann: For the other operating income infantry before obviously it was a very important point.
Christian Ehmann: Or part of your earnings.
Speaker Change: 424, before $148 million and other income from tax credits. My question here would be what do you think is the sustainable level of income tax or tax credits R&D tax credits for the foreseeable future and what can be put into our modeling.
Christian Ehmann: Are there any risks to these kind of tax credits at the moment.
Speaker Change: For example, in the UK and France.
Speaker Change: My second question would be to the savings composition for the $50 million gross.
Speaker Change: What potential so what's what are the net effect to foresee.
Speaker Change: Which which cost do you expect to increase over time for what can we say okay. This one is the <unk>.
Speaker Change: The net effect over the next years, then in regard to the drug portfolio expectations.
Speaker Change: Narrowed it down to a 100 products could you give us a little bit more detail about the faith composition, so which ones are in clinical trials, which one are in discovery.
Speaker Change: We can have a more granular approach to our own risk adjusted model for this kind of value and then my last question is in regards to the F. D. A decision. So my thought my question would be how sophisticated are those models today. So is it really possible to.
Speaker Change: Really phase out animal testing over the foreseeable future and let's say four to five years.
Speaker Change: And to really get rid of the use of animals and with regard and where all the models at the moment and what can be done with it. Thank you very much. Thank you Christian.
And I would say the first two I'll hand over to Paul and then number three and four.
Speaker Change: Two courts, Oh I'm I'm.
Paul Hitchen: Shall we start with the financials, Yeah Christian Hi, This is Paul nice to meet you. So first of all on the operating income on the tax credits.
Paul Hitchen: You are probably correct with your assumptions around the generation market generation of our tax credits at this stage, we don't see any risk to that and I would say that they would grow in line with our business growth and where we actually perform the work and the R&D work and Thats, how we plan.
Paul Hitchen: Modal.
Paul Hitchen: Your second question around the composition of the 50 million euros gross versus net maybe maybe just to dwell on this point a little bit.
I'd say a couple of things first of all we're really pleased with the cost initiatives that we've achieved in 2024 and further committed in 2025.
Paul Hitchen: And as we build on those efforts and look forward to driving more productivity and cost efficiency over the planning period.
Paul Hitchen: So as you see on the page that we presented we put a full suite of believers.
Paul Hitchen: And the $50 million is the cost our gross cost out beyond 2025.
Paul Hitchen: When you think about the gross versus net question, what I would say is over the planning period when you consider the.
Paul Hitchen: A combination of <unk>.
Paul Hitchen: Cost out productivity inflation, you probably get to the next $50 million you also see on this page.
Paul Hitchen: I hope that answers the question.
Paul Hitchen: Could I think come back to you.
Paul Hitchen: Yeah, So let me start by.
Paul Hitchen: Trying to address the question regarding the pipeline.
Paul Hitchen: As a Christian already stated that currently six assets in the next stage freezes early stages phase one.
Paul Hitchen: We and then.
Paul Hitchen: Six clinical or preclinical stage assets, we do expect or we do have we do see opportunities.
Paul Hitchen: That within the next 24 months about 15 assets have the potential to move forward from the pre clinic into the clinic and then.
Paul Hitchen: Do we.
Paul Hitchen: Have quite a number of a larger number of earlier stage assets that will then fill in the pipeline in the pre clinic.
Paul Hitchen: Yes.
Paul Hitchen: Then to.
Paul Hitchen: To ask again the line broke a little bit up so fixed assets in clinical stages and six P. S in preclinical stages six.
Paul Hitchen: In preclinical.
Paul Hitchen: Okay. Thanks.
Paul Hitchen: But over the course over the next 24 months, we have about 15.
Assets that could move forward and in total into clinical stages. So that gives you an idea about the breadth and depth of the pipeline in.
Paul Hitchen: Calvary.
Paul Hitchen: So we're at earlier stages.
Paul Hitchen: So then we have got the FDA topic animal testing obviously.
Paul Hitchen: A lot of noise around that.
Paul Hitchen: Fair to say that.
Paul Hitchen: It's not a new topic for us honestly, we've been looking at this since a couple of years.
Paul Hitchen: And talked a lot less about that but this is pretty real led court explain.
Paul Hitchen: What is behind that and what our activities are in this field.
Paul Hitchen: So you are moving to the FDA announcement, they announced that they intend to phase out animal testing requirements for monoclonal antibody development, but also for other modalities.
Paul Hitchen: They plan to replace current standard animal models with new alternative methodologies and here. They mentioned explicitly human micro physiological systems, which are usually cell based models and three D or three D human cell based systems.
Paul Hitchen: And they also mentioned computational modeling and in particular AI based approaches to Biosimilars.
Speaker Change: He will take me not only support this initiative.
Paul Hitchen: The FDA, but be highly welcome this development.
Paul Hitchen: It will take us really uniquely positioned to serve this developing market and it would take we can bring to bear a fully integrated suite of new alternative methodologies, reaching from monocular patient data human micro physiological systems, two in silicon based prediction tools, but.
Paul Hitchen: Also computational modeling.
Paul Hitchen: And you can take the have established really a broad suite of few micro physiological systems, which became combining with superior sophisticated imaging.
Paul Hitchen: But also detailed on make space analysis as well as AI machine learning supported data analysis.
Paul Hitchen: Based on our human Ips C platform B currently run more than 25 cell types, including liver granted.
Paul Hitchen: Cardiac micro tissues kidney organic but also newer spheres and.
Paul Hitchen: And we are operating most of these assays and 384 were formats and these are high throughput.
Paul Hitchen: In the high throughput motives and Beacon combined these models.
Paul Hitchen: With high resolution high throughput Omics technologies.
Paul Hitchen: So in order to be clear I want to give you an example.
Paul Hitchen: <unk> is absolutely leading in predicting for example drug induced liver injury.
Paul Hitchen: This is the most common cause of liver failure.
Paul Hitchen: Although we cover essentially all standard approaches for predicting daily or drug induced liver injury.
Paul Hitchen: Our most successful platform here is based on LIBOR gone nights in combination that Omics based analysis.
Paul Hitchen: We have the most competitive.
Paul Hitchen: Here have stand up with the standup platforms reach predictive accuracies of currently around 75%.
Speaker Change: <unk> platform reaches the predictive accuracy of obra, 87% and we believe we will soon surpass 90% of predictive accuracy with our platform.
Our knowledge this is unprecedented.
Speaker Change: B. We are currently expanding this platform into additional areas such as cardiac neuro keep need et cetera.
Speaker Change: And so we really believe that he will take will set itself apart, especially in these areas.
Speaker Change: Thank you Cort.
Speaker Change: Back to the operator.
Speaker Change: Thank you.
Speaker Change: The next question comes from Mike <unk> Bank of America. Please go ahead.
Speaker Change: Great.
Speaker Change: So for taking the question I Hope you can hear me.
Speaker Change: I've got a couple I'll squeeze them together. So one is on your comments on expectations for underlying market for the rest of this year I think you kind of pointed to some continued headwinds in the first half of the year, maybe second half a little bit better and then you talked about I think a 5% to 7% underlying growth for 2028.
I'm, just curious sort of like what are the what are the puts and takes on that.
Speaker Change: Thinking about.
Speaker Change: Tariffs may not be a huge hit but thinking about NIH impacts in the U S. Overall biotech funding environment in the U S and then attend.
Speaker Change: Actual downstream impacts of things like HHS cuts FDA cuts, how that could impact the R&D.
Speaker Change: Broader biopharma R&D universe for the next couple of years I think there's a lot of concerns there. So I'm curious how you build up to that 5% to 7% growth and then the second question I had was.
Speaker Change: More on EBIT, specifically, you know the cost outs you mentioned.
Speaker Change: You've taken this year could you just give us a little bit more color on.
Speaker Change: How you're weighing those in over the course of the year.
Speaker Change: Any thoughts on timing and then just confidence that you won't be able to cut you won't cut too deeply and you're still going to have.
Speaker Change: Innovation in R&D to continue to drive revenue growth. Thanks.
Paul: Thank you, Mike I will start and then hand over to Paul just on the expectation of the market. Obviously, one affects the other sentiment right.
Paul: When you first of all look at how we've built up to 5% to 7%.
Paul: Our underlying.
Paul: Long term growth rate for the addressable market and as I alluded to we're basically starting from the funding situation or the spending situation in biopharma.
Paul: Fair to say you can go back in history that has always been in the range of five 6% for a five 6% for the for the Biopharma market.
Paul: Then there was a sharp spike during COVID-19 on the hangover effect more recently our.
Paul: <unk> is that the spending in R&D, so big pharma spending biotech will come back to this 3% to 4% range. The five to seven is spend the conclusion of <unk>.
Paul: Outsourcing will accelerate.
For the CLO market, so, but you'd have to debate the underlying spending.
Paul: And obviously then.
Paul: The extra that comes with an increasing rate of.
Paul: Of outsourcing.
Paul: More short term tariffs.
Paul: NIH FTA cuts I mentioned.
Paul: We've looked at that since quite a bit.
Paul: We've sized it and it's fair to say that the impact historic impact is fairly limited.
Paul: Our current tariff situation, we looked at a small number.
Paul: Our current exposure to revenues to NIH frankly, it's very limited.
Paul: So that direct impacts we assessed to be small.
Paul: Then the question is obviously, if they're an indirect impact.
Paul: Might happen for example, because purchase University purchase Academy academic patches get Hot Springs, less innovation coming from universities that is leading them in the long term too.
Paul: Fewer carve outs.
Paul: Fewer startups in the biotech industry that could be an indirect impact.
Paul: But at this point in time, the direct impact you see is sandy manageable.
Paul: Paul any further points on the.
Paul: First topic and especially on the second question around cost outpacing yeah.
Paul: I think first of all.
Paul: Mike just on the cost topic that you raised which is I think specifically around the 2025 cost out which is on top of the priority reset and excluding the 50 million that we.
Paul: Third to over the mid range plan period.
Paul: What I would say is.
Paul: First of all we've got very good line of sight to.
Paul: So the cost plans that we have.
Paul: For 2025. It includes measures have already been completed such as colon that I referred to.
Paul: In the first quarter.
Paul: It also includes tighter cost control lower spend managing head counts and replacements through the organization.
It will generally be directed towards cost of goods and SG&A and as a consequence, you see on the R&D innovation funding, we confirmed the guidance around $40 $50 million. So again very very targeted in 2025.
Paul: And a lot of this cost has already been identified and much of it actually executed in the first half of 2025.
Speaker Change: Great. Thank you so much.
Speaker Change: Alright expected yourself. The next question comes from Charles Weston RPC Europe. Please go ahead.
Speaker Change: Hello, and for taking the questions mining, we're sad to see the medium term outlook.
Speaker Change: Festival specific question of milestones on page 29 of the presentation.
Speaker Change: You guys see.
Speaker Change: Hi, Doug this is a bookshelf showing how much.
Speaker Change: I'll spend might be payable each year.
Speaker Change: It looks like for 2026, if I read that acts as a parent greatly simplify <unk> chunk of many uneven.
Speaker Change: In 2026 is that correct.
Speaker Change: And how much is in guidance for 2025 and outlook for 2028.
Speaker Change: And then.
Speaker Change: Moving on from that if I look at 2028.
Speaker Change: Presumably your CAC at 20.
Speaker Change: 24 to 28, what's the likely contribution from each patient what will this business potentially look like in 2028.
Speaker Change:
Speaker Change: And then <unk>.
Speaker Change: That's on the top line, but also could you give us a sense of.
Speaker Change: The margin improvements across each of the two different divisions.
Speaker Change: And in particular, how we might get back in terms of growth and the molecule improvement over the full year periods.
Speaker Change: More likely be backend Blake in for example, thank you. Thank.
Speaker Change: Thank you Charles and good to speak again first of all.
Paul Hitchen: The short comment from my side, and then handing over to Paul again.
Paul Hitchen: On page 29.
Paul Hitchen:
Paul Hitchen: Keep in mind. This is a non risk adjusted revenue line. So is basically.
Paul Hitchen: No.
Paul Hitchen: And I've injected as small sentence.
Paul Hitchen: Probably also noted we've taken a conservative approach on this obviously this is science.
Paul Hitchen: And our first comment.
Paul Hitchen: There is a translation from non risk adjusted into risk adjusted in our plan.
Paul Hitchen: Which we've done carefully but the other thing that I wanted to mention is obviously.
Paul Hitchen: You see that it's also a bumpy road here because those milestone payments can come in a year.
Paul Hitchen: They can come in the quarter, but they can also slipped fallboard OPEC forward. So this is giving you an indication.
Paul Hitchen: We also have given you a little bit too to calculate obviously on that slide.
Paul Hitchen: But my first and foremost common is that the assumption for the mid range plan is quite conservative.
Paul Hitchen: Yes.
Yeah, I'd like to reiterate that so once we see the opportunity as being very significant.
Paul Hitchen: Our cautious when we plan the realization of that given the potential timing volatility.
Paul Hitchen: On those assets and the progression of the science.
Paul Hitchen: And so when you think about the planning period, we have.
Paul Hitchen: Relatively nominal amount for value add ons in 2025 net increases in 2028, but it's still.
Paul Hitchen: A small piece of the overall revenue pie.
Paul Hitchen: At payment period.
Paul Hitchen: When you look at your second question around contribution of topline.
Christian: For each of the divisions I would say Christian outlined.
Christian: Michelle R&D business, we'd be looking to grow above the market rates over the planning period, and the market rate being 5% to 7%.
Christian: And then the.
Christian: Just EBIT like biologics business will again grow.
Christian: Significantly above the market and reflects the realization of our backlog and existing partnerships and new deals. During this period of time, so an accelerated growth rate versus the overall market indication that we've given you.
Christian: In terms of your elements of your question around margin improvements after the business, we don't provide guidance for.
Christian: For the individual.
Christian: Segments themselves, but I would say.
Christian: Following when you think about margin expansion from the 2024 rate of about 3% to 20% think about the following.
Christian: Growth and mix of the business drives about two thirds of that expansion by weight and the cost and productivity drives about a third of that expansion.
Christian: And when you think about the growth element.
Christian: Just business is driving about two thirds of the overall growth.
Christian: And when you think about the cost and productivity expansion you see the cost effect in the earlier years, and then the productivity and the automation in the later part of years, but I think that hopefully gives you enough to model out a little bit.
Christian: The overall.
Christian: Profile of the business as we see it.
Christian: Okay.
Christian: Okay. Thank you very much.
Christian: Thanks, Charles Peck to use the use of face.
Speaker Change: As a reminder, if you wish to ask a question. Please press star and one next question comes from Swiss Brendan TD Cowen. Please go ahead.
Christian: I think for all the detail on the call and taking my questions first.
Speaker Change: First of all from a kind of expanding on a couple of the earlier questions. I did just wanted to ask about some of the different growth drivers over the next 12 months to 18 months lets say for just the vertex biologics business specifically.
Speaker Change: It really gets which among these drivers you see it more and less Derisked based on your recent conversations with partners and I guess I'm just trying to understand.
Speaker Change: A little bit better than some of the levers that you can pull internally to maintain growth there like overall, even if partners the northern market potentially take a little longer to stabilize or recover.
Speaker Change: And then just maybe one other one to follow up on your comments earlier about Fda's updated guidance last week on animal testing.
Speaker Change: Wondering if you see any potential for upside to any of your assumptions. This year as companies look to shift strategy and stay aligned with FDA or do you think that's going to take a little bit longer a little bit more time, and that's maybe something that you would likely see more come into play next year. Thank you yeah, absolutely and first of all on just I would say we have pretty pretty.
Speaker Change: Good line of sight on just business to next 12 months based on the commercial conversations that we've had in 2024 so.
Speaker Change: The components are pretty much along the lines of what we have.
Speaker Change: <unk> said before is obviously pre commitments for.
Speaker Change: Sandoz, but theres also.
Speaker Change: A large group of other customers, which we've lined up in the last few years contributing to this growth.
Speaker Change: Not published a maybe there's a chance over the course of the year to.
Speaker Change: To make the one of our more visible. So this is pretty much already visible to us.
Paul Hitchen: And therefore, it comes with high confidence as Paul was saying.
Paul Hitchen: And on the FCA topic.
Paul Hitchen: Well.
Paul Hitchen: Let me phrase it that way.
Paul Hitchen: We are actively using.
Paul Hitchen: Our tools already for prediction and court.
Paul Hitchen: Court was alluding to.
Paul Hitchen: The whole mix.
Paul Hitchen: <unk>.
Paul Hitchen: Two towards better.
Paul Hitchen: And foster outcome.
Paul Hitchen: The question is is there an immediate tipping point.
Paul Hitchen: It'd be a bit careful on this.
Paul Hitchen: At this point in time, we don't have sufficient information how this is going to play out.
Paul Hitchen: With the FTA.
Paul Hitchen: Maybe.
Paul Hitchen: Maybe just one comment from my end.
Paul Hitchen: Ultimately.
Speaker Change: This is the development that we've been watching for quite some time you would take has been to some extent actually been pioneering.
Paul Hitchen: In.
Paul Hitchen: Bringing omics technologies put us into the mainstream of the drug discovery process.
Paul Hitchen: And.
Paul Hitchen: We've been in the past a little bit surprised.
Paul Hitchen: About the hesitancy of.
Paul Hitchen: Using these technologies in a very concerted effort.
Paul Hitchen: Two.
Paul Hitchen: To predict efficacy and safety profiles, but.
Paul Hitchen: But we do see even ahead of the FDA announces behalf seen continue to see an increased interest in particular by pharma companies into into using these kind of technologies.
Paul Hitchen: More.
Paul Hitchen: More extensively in the preclinical setting to select compounds for further development and so.
Paul Hitchen: This will be a very important milestone.
Paul Hitchen: For the whole industry in that regard.
Paul Hitchen: But it is a little hard to predict how quickly this trend.
Paul Hitchen: Translate into significantly increased business here.
Paul Hitchen: I would say.
Paul Hitchen: We already see the first signs of it but.
Paul Hitchen: In order for this to materialize, but probably still take your Q2.
Paul Hitchen: A few months more.
Paul Hitchen: But we are very optimistic with this.
Speaker Change: Okay. Thank you very much.
Paul Hitchen: And back to use of face.
Speaker Change: The next question comes from Joseph Joseph had them from Rx Securities. Please go ahead.
Paul Hitchen: Good afternoon, Thanks for taking my questions.
Joseph: Just wondered if I could dig into a little bit more about how you're streamlining your pipeline assets you talked in the report about high value therapeutic areas could you the EBIT more specific about the areas of focus and perhaps what you're moving away from.
And then also the focus on high value services.
Joseph: Does that mean that the transaction works has has really suffered over the last couple of years ever since the cyberattack iridium with weaker environment.
Joseph: Is any of that business.
Joseph: Being discontinued or wound down.
Joseph: Any detail you can give on that'd be great. Thanks.
Joseph: Absolutely and maybe of course start with streamlining.
Joseph: Portfolio.
Joseph: Yeah. So.
Speaker Change: Let me start by saying so that Christian mentioned that be cleaned up the pipeline and I think thats.
Joseph: Fear assessment.
Joseph: There were quite a few sort of historic legacy assets still in the pipeline.
Joseph: <unk> have been essentially now completely removed.
Joseph: And.
Joseph: The latest pit was essentially.
Joseph: Showing of EBT tool one.
Joseph: And SSA.
Joseph: It wasn't very well differentiated.
Joseph: On the sort of being pursued in the Asian markets.
Joseph: Everything else that we currently have in the pipeline and I mentioned, the six clinical stage assets and the six preclinical stage assets <unk> and <unk>.
Joseph: Large underlying iceberg of earlier stage assets are too.
Joseph: Two two of the 100 asset 70% of these are in partnership with pharma companies.
Joseph: And here in particular of course behalf partnerships in the oncology space.
Joseph: With BMS in the new aerospace with BMS, but in the metabolic disease space kidney disease space with companies such as normal Lilly Bayer Novartis.
Joseph: J&J and others.
Joseph: And and so we consider these really highly innovative programs.
Joseph: Yes.
Joseph: Very high potential and sort of.
Joseph: Being differentiated turning to differentiated assets.
Joseph: In the clinical sense.
Joseph: <unk>.
Joseph: You will take.
Joseph: Essentially working constantly with.
Joseph: We're working constantly with our partners to expand these pipelines drive the pool, where together with our partners. So all of these are decisions that we've taken together with our partners.
Joseph: <unk>.
Joseph: Earlier stage assets that we are driving in parts through our own R&D funding.
Joseph: More proof of principals points that we can demonstrate to our partners that our platforms are highly productive they help us to develop highly differentiated early stage assets and very often they also serve as starting points for more so.
Joseph: TJ collaborations where these are then basically taken up as part of the pipeline building process.
Speaker Change: Thank you Cort and two the other topic on on services as I mentioned earlier.
Speaker Change: We have a full suite of services here, but we also have to unpack this a little bit because.
Speaker Change: They are not all the same them or having the same characteristics and dynamics in fact, there is actually quite.
Speaker Change: Different dynamics in what we call shared R&D services. So you have some.
Speaker Change: As I mentioned earlier.
Speaker Change: Well, we would call essentials.
Speaker Change: Where.
Speaker Change: He asked from the customers pretty much standardized service at high quality.
Speaker Change: Speed of offering and so forth our intent here is to ensure that on the operation side, we felt the standardized.
Speaker Change: So.
Speaker Change: <unk>.
Speaker Change: But we were able to serve them at best cost.
Speaker Change: But they are also part of packages of integrated deals and strategic deals and that's typically how we also sell them in the market and when I'm.
Speaker Change: Discriminating here are the Hum.
Speaker Change: Basically explaining that we are preferentially investing into segments with higher exposure to technology high exposure to a differentiation potential.
Speaker Change: So.
Speaker Change: To make it even more.
Speaker Change: And easy to understand is why.
Speaker Change: We have the opportunity to invest into.
The next generation of technology devices mass specs for all makes platform as opposed to.
Speaker Change: For example.
Speaker Change: Ponting our capacity.
Speaker Change: In.
Speaker Change: In API, it's quite clear, what we're going to do it in future and that kind of differentiation.
Speaker Change: We're now doing on a much more granular level than we've done in the past.
Speaker Change: I hope that explains the labor charges.
Speaker Change: Yes, it does thanks very much.
Speaker Change: The next question comes from Charles Weston RPC Europe. Please go ahead.
Speaker Change: Come back to us.
Speaker Change: Thanks Christine.
Speaker Change: Taking the follow ups.
Speaker Change: Three more finite place festival on adjusted EBITA Biologics.
Speaker Change: Can you help me, perhaps run through again, what's happening this year.
Speaker Change: Operating leverage you've got 40 to 80 million more revenue come through probably not much in the way of EBITDA.
Speaker Change: So what is the right space.
Speaker Change: Cost.
Speaker Change: What is the revenue drop through to EBITDA once fixed costs are established.
Speaker Change: But we can think about for multiple purposes.
Speaker Change: Secondly from a great basis.
Speaker Change: It was just somewhat surprised to me about the one off savings in 2024, which I understand are there any further one offsetting and seems like it can be five which we should think about and factoring in.
Speaker Change: Thanks.
Speaker Change: Martin and treatments and loss rate.
Speaker Change: More holistic picture of question here.
Speaker Change: What is the synergy between the patients.
Speaker Change: Presumably as part of your strategic review you talked about the rationale for that businesses. So perhaps you could.
Speaker Change: Explain sort of what your thought process was that lease.
Paul: Thank you for the questions I think the first two we can take quite quickly Paul.
Speaker Change: Yeah. Thank you Sir.
Speaker Change: A question first of all regarding the just the <unk> business. So as you rightly say we are.
Speaker Change: Continuing to invest in this business over the course of 2025 to support commercial.
Speaker Change: Business. We are committed when you think about that ramp up costs. A child. That's made up of three elements. One is the the people ramp up too is the.
Speaker Change: Costs associated with ramp up whether that's consulting.
Speaker Change: As terms facilities and so on and so forth and the third element is around material costs.
Speaker Change: <unk> spend as we get that we ramp up to full production. So those those three elements drive the year over year kind of cost dynamic what I would say in terms of what is the cost base looked like the just EBIT tech business going forward and whats modal I would say that by the end of 2020.
Speaker Change: Five when you think about the fixed cost base of the business you are substantially.
Speaker Change: Complete so as you think about our model forward, Greg if you start seeing.
Speaker Change: <unk> operating leverage within the business.
Speaker Change: In terms of your second question, which is around the one off savings in 2020 full short answer to this one is no further one offs are planned in 2025.
Speaker Change: And then on the last topic.
Speaker Change: Just for instance, Chad on the well.
Speaker Change: Consider the overall umbrella technology and science leadership.
Speaker Change: Enabling our part enabling our partners to.
Speaker Change: To make their journey more successful when you think about this year, the R&D business as I alluded to earlier.
Speaker Change: Think about on mix thinking about AI that we're using to think about <unk> think about our one of our patient database why are we doing it because we are confident in <unk>.
Speaker Change: Demonstrated that this will actually make that journey.
Speaker Change: Our drug discovery and development more successful likewise, when you think about just it would take biologics think about art.
Speaker Change: Investments into the cell lines the media transaction.
Speaker Change: The vector is.
Speaker Change: Creasing the expression rates of our cell lines in order to make the journey more successful at that and you can almost say in the end on the left side small molecules on the right side large molecules right.
Speaker Change: The synergy is technology leadership to enable partners to become more successful.
Speaker Change: Okay. Okay. Thank you.
Speaker Change: Checking with poker and Joseph.
Speaker Change: I got the impression that were true Joseph can you.
Speaker Change: Confirm yes, ladies and gentlemen that was the last question I would now like to turn the conference back over to Volker Braun for any closing remarks.
Volker Braun: Thank you Joseph and thank you to all on the call for your interest and it would take for the discussions we have the opportunity to speak again very soon in three weeks from now on the sixth of May for the release of the Q1 results in the meantime for any questions. You may have feel free to reach out anytime and we.
Speaker Change: We will send spy and.
Speaker Change: The next day, so wish you a happy and.
Speaker Change: Speak soon thank you.
Speaker Change: Ladies and gentlemen, the conference is now over thank you for choosing chorus call and thank you for participating in the conference you May now disconnect your lines Goodbye.